Amedisys Inc (NASDAQ:AMED) Q2 2022 Earnings Conference Call July 28, 2022 11:00 AM ET
Company Participants
Nick Muscato - Chief Strategy Officer
Chris Gerard - President and Chief Executive Officer
Scott Ginn - Executive Vice President and Chief Financial Officer
David Kemmerly - Chief Legal and Government Affairs Officer
Conference Call Participants
Brian Tanquilut - Jefferies
Matt Larew - William Blair
Justin Bowers - Deutsche Bank
John Ransom - Raymond James
Benjamin Rossi - BMO
Sarah James - Barclays
A.J. Rice - Crédit Suisse
Michael Murray - RBC
Andrew Mok - UBS
Tao Qiu - Stifel
Scott Fidel - Stephens
Whit Mayo - SVB Securities
Nabil Gutierrez - BofA Securities
Operator
Greetings. Welcome to Amedisys Second Quarter 2022 Earnings Call. [Operator Instructions] Please note this conference is being recorded.
At this time, I'll turn the conference over to Nick Muscato with Investor Relations. Nick, you may now begin.
Nick Muscato
Thank you, operator, and welcome to the Amedisys investor conference call to discuss the results of the second quarter ended June 30, 2022. A copy of our press release, supplemental slides and related Form 8-K filings with the SEC are available on the Investor Relations page of our website. Speaking on today's call from Amedisys will be President and Chief Executive Officer, Chris Gerard; and Executive Vice President and Chief Financial Officer, Scott Ginn. Also joining us is Dave Kemmerly, Chief Legal and Government Affairs Officer.
Before we get started with our call, I would like to remind everyone that statements made on this conference call today may constitute forward-looking statements and are protected under the Safe Harbor of the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Amedisys today. The company assumes no obligation to update information provided on this call to reflect subsequent events other than as required under applicable securities laws.
These forward-looking statements may involve a number of risks and uncertainties which may cause the company's results or actual outcomes to differ materially from such statements. These risks and uncertainties include factors detailed in our SEC filings, including our Forms 10-K, 10-Q and 8-K. In addition, as required by SEC Regulation G, a reconciliation of any non-GAAP measure mentioned during our call to the most comparable GAAP measures will be available in our Forms 10-K, 10-Q and 8-K. Thank you.
And now I'll turn the call over to President and CEO, Chris Gerard.